Secondary Malignant Neoplasm — Trials

Secondary Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

14,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,270
Recruiting: 2,320
Ph III recruiting: 270
Growth YoY: +13.6%
Industry share: 22%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,961)

clinicaltrialsPublishedShowing 101–150 of 635 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06253871	A Phase 1/1b Study of IAM1363 in HER2 Cancers	recruiting	Phase 1	383	Iambic Therapeutics, IncINDUSTRY	8	Sep 9, 2026	clinicaltrials
NCT06597721	ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours	recruiting	Phase 1	210	Adcendo ApSINDUSTRY	2	Sep 9, 2026	clinicaltrials
NCT06696768